The association between migraine and patent foramen ovale (PFO) has been documented. We aimed to investigate platelet activation, prothrombotic phenotype, and oxidative stress status of migraineurs with PFO on 100 mg/day aspirin, before and 6 months after PFO closure. Data show that, before PFO closure, expression of the classical platelet activation markers is comparable in patients and aspirin-treated healthy subjects. Conversely, MHA-PFO patients display an increased prothrombotic phenotype (higher tissue factor(pos) platelets and microvesicles and thrombin-generation potential), sustained by an altered oxidative stress status. This phenotype, which is more controlled by P2Y(12)-blockade than by aspirin, reverted after PFO closure together with a complete migraine remission. (pLatelEts And MigRaine iN patEnt foRamen Ovale [LEARNER]; NCT03521193) (C) 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.

Migraine in Patients Undergoing PFO Closure: Characterization of a Platelet-Associated Pathophysiological Mechanism: The LEARNER Study / D. Trabattoni, M. Brambilla, P. Canzano, A. Becchetti, G. Teruzzi, B. Porro, S. Fiorelli, M. Muratori, C.C. Tedesco, F. Veglia, P. Montorsi, A.L. Bartorelli, E. Tremoli, M. Camera. - In: JACC. BASIC TO TRANSLATIONAL SCIENCE. - ISSN 2452-302X. - 7:6(2022 Jun), pp. 525-540. [10.1016/j.jacbts.2022.02.002]

Migraine in Patients Undergoing PFO Closure: Characterization of a Platelet-Associated Pathophysiological Mechanism: The LEARNER Study

S. Fiorelli;P. Montorsi;A.L. Bartorelli;M. Camera
Ultimo
2022

Abstract

The association between migraine and patent foramen ovale (PFO) has been documented. We aimed to investigate platelet activation, prothrombotic phenotype, and oxidative stress status of migraineurs with PFO on 100 mg/day aspirin, before and 6 months after PFO closure. Data show that, before PFO closure, expression of the classical platelet activation markers is comparable in patients and aspirin-treated healthy subjects. Conversely, MHA-PFO patients display an increased prothrombotic phenotype (higher tissue factor(pos) platelets and microvesicles and thrombin-generation potential), sustained by an altered oxidative stress status. This phenotype, which is more controlled by P2Y(12)-blockade than by aspirin, reverted after PFO closure together with a complete migraine remission. (pLatelEts And MigRaine iN patEnt foRamen Ovale [LEARNER]; NCT03521193) (C) 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
GSH, reduced glutathione; GSSG, oxidized glutathione; HS, healthy subject(s); MHA, migraine headache with aura; MV, microvesicles; NAC, N-acetylcysteine; PFO, patent foramen ovale; PS, phosphatidylserine; ROS, reactive oxygen species; TF, tissue factor; WB, whole blood; cTTE, contrast transthoracic echocardiography; migraine with aura; oxidative stress; patent foramen ovale; platelets; tissue factor;
Settore MED/11 - Malattie dell'Apparato Cardiovascolare
Article (author)
File in questo prodotto:
File Dimensione Formato  
35818509.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 2.26 MB
Formato Adobe PDF
2.26 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/946298
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact